Company intelligence / Profile preview

Entogene

Rostock, Germany

Ownership: Private
Employees: ~493
Development stage: Other

Overview

CENTOGENE was a rare disease diagnostics company that integrated multiomic technologies with its proprietary Biodatabank. The company finalized a private equity buyout and sold its operating assets to Charme Capital for €8.7M, with plans for liquidation.

Therapeutic areas: ImmunologyNeurologyMetabolic DisordersRare DiseasesOncology
Industry: Molecular Diagnostics

Partnerships

LiferaTakedaThe Michael J. Fox FoundationDenali TherapeuticsTWIST BioscienceIllumina

Beyond the preview

Go deeper on Entogene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Entogene.

Explore the full profile